Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by research analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital’s price objective suggests a potential upside of 100.00% from the company’s current price.

Other research analysts have also issued reports about the company. D. Boral Capital reissued a “buy” rating and set a $15.00 price target on shares of Coya Therapeutics in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, November 11th.

Coya Therapeutics Stock Up 7.2 %

Shares of COYA stock traded up $0.47 during trading hours on Thursday, reaching $7.00. 400,429 shares of the stock traded hands, compared to its average volume of 67,476. The firm has a market capitalization of $116.97 million, a PE ratio of -10.77 and a beta of 0.47. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69. The business has a fifty day moving average price of $5.86 and a 200 day moving average price of $6.40.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.15. Research analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Coya Therapeutics news, CEO Arun Swaminathan bought 5,000 shares of Coya Therapeutics stock in a transaction on Monday, November 11th. The stock was purchased at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the purchase, the chief executive officer now directly owns 5,000 shares of the company’s stock, valued at $36,700. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders bought 9,510 shares of company stock worth $69,615. Corporate insiders own 9.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Newbridge Financial Services Group Inc. acquired a new position in Coya Therapeutics during the fourth quarter worth $401,000. Geode Capital Management LLC boosted its stake in shares of Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares in the last quarter. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics during the 3rd quarter valued at about $169,000. Finally, Renaissance Technologies LLC bought a new position in shares of Coya Therapeutics in the 2nd quarter valued at approximately $101,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.